REVO-CAPITAL
4.10.2021 14:03:01 CEST | Business Wire | Press release
Originally starting the fund raise process with a target size of 60 million Euros, Revo Capital ended up closing an oversubscribed second fund at 90 million Euros, making it Turkey's largest VC fund to date. The continued interest and support that Revo Capital has drawn from institutional and global investors reflects the trust in Revo's strategy and the success of its first fund. Thanks to the financial returns of its first fund, Revo Capital ranks in the top decile among the same vintage VC funds globally. Revo managed to finalize 3 exits, 3 new investments in the last 3 months in tandem with Fund II closing . As the largest VC fund in Turkey, Revo Capital will continue making investments in Turkey, Eastern Europe and Baltics .
Revo Capital was proud to onboard returning cornerstone investors IFC and EBRD and welcomes premier institutional investors Turkish Growth and Innovation Fund (TGIF) as advised by European Investment Fund (EIF), German Investment Corporation (DEG), Turkey Development Fund, as well as several prominent local corporate investors, family offices and entrepreneurs. Koray Bahar and Ahmet Bilgen, founders of Foriba (a Revo Fund I portfolio company exited to Sovos Inc) contributed to Revo's second fund, proving very positive circular impact of financing great entrepreneurs, strengthening the development of the ecosystem.
Revo Capital to continue its proven investment strategy in Fund II
“We are proud of the everlasting support we received from our long-time LPs IFC and EBRD, and the interest from new long-term LPs EIF and DEG,” said Cenk Bayrakdar, Revo Capital’s Founding Partner . "The last decade was laying the foundation of our belief that providing capital and operational/growth support to fast-growing software and tech-enabled startups from Turkey, Eastern Europe and Baltics will help them become industry and global leaders. As the first fund investing in Turkish unicorn Getir, we have firsthand experienced how its success strengthened the Turkish startup ecosystem, motivating entrepreneurs as a role model to build global category-defining products and services. As Revo Capital, we invest in certain select verticals and the latest developments have proven us right about these verticals. We work hand in hand with entrepreneurs and look forward to continuing our proven investment strategy with Fund II.”
Revo Capital invests in Series A and B rounds of startups with a proven product-market fit and potential for global market disruption. Revo Capital's close relationship with its vast investment network enables easier access to capital for its portfolio companies as they scale up to overseas markets. Revo Capital has already made 5 investments from its second fund : CY Vision, Massive Bio, Getir, Akinon and Vivoo.
Revo Capital’s target verticals are fintech, SaaS, marketplaces, B2B cloud, Martech, Big Data and AI, and (as a new vertical for Fund II) Health IT. “The rapid pace of digitization in the last couple of years has brought these sectors into focus and we believe that they will see tremendous growth going forward,” Bayrakdar said.
The second fund continues the success of the first fund, which saw 6 profitable exits, among them many stars of the Turkish digital ecosystem such as Foriba, Paraşüt and Getir.
Raising its reputation among the leading investors in Turkey, Central and Eastern European regions thanks to the success of its second fund, Revo Capital will keep on utilizing its hands-on approach to create international funding opportunities in the follow-up rounds for its new investments. Cenk Bayrakdar added: "We are perfectly placed to act as a catalyst to accommodate the new wave of ambitious local founders who want to target global markets. Through our collaborative approach and international network, we can help bridge them to larger investors and open them up to capture growth opportunities globally."
For more info, you can visit: https://www.revo.vc/
View source version on businesswire.com: https://www.businesswire.com/news/home/20211004005359/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom